

Comments and requests for hearing on applications to import narcotic raw material are not appropriate. 72 FR 3417 (January 25, 2007).

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on December 6, 2018, Stepan Company, 100 West Hunter Avenue, Maywood, New Jersey 07607–1021 applied to be registered as an importer of the following basic class of controlled substance:

Controlled substance	Drug code	Schedule
Coca Leaves	9040	II

The company plans to import the listed controlled substance in bulk for the manufacture of controlled substances for distribution to its customers.

Dated: February 4, 2019.

John J. Martin,

Assistant Administrator.

[FR Doc. 2019–01847 Filed 2–8–19; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: The registrant listed below has applied for and been granted a registration by the Drug Enforcement Administration (DEA) as bulk manufacturer of a schedule I controlled substance.

SUPPLEMENTARY INFORMATION: The company listed below applied to be registered as a bulk manufacturer of a various basic class of a schedule I controlled substance. Information on the previously published notice is listed in the table below. No comments or objections were submitted for this notice.

Company	FR Docket	Published
Specgx, LLC	83 FR 51983	October 15, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed company.

Dated: January 30, 2019.

John J. Martin,

Assistant Administrator.

[FR Doc. 2019–01862 Filed 2–8–19; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. 19–2]

Paul Surinder Singh, D.O.; Decision And Order

On August 8, 2018, the Assistant Administrator, Diversion Control Division, Drug Enforcement Administration (DEA), issued an Order to Show Cause to Paul Surinder Singh, D.O. (Respondent), of Tehachapi, California. The Show Cause Order proposed the revocation of Respondent's DEA Certificate of Registration No. BS7367623 on the ground that he has "no state authority to handle controlled substances." Order to Show Cause, at 1 (citing 21 U.S.C. 824(a)(3)). For the same reason, the Order also proposed the denial of any of Respondent's "applications for renewal or modification of such registration and any applications for any other DEA registrations." *Id.*

With respect to the Agency's jurisdiction, the Show Cause Order alleged that Respondent is the holder of Certificate of Registration No. BS7367623, pursuant to which he is authorized to dispense controlled substances as a practitioner in schedules II through V, at the registered address of 276 C South Mill Street, Tehachapi, California. *Id.* The Order also alleged

that this registration does not expire until February 28, 2019. *Id.*

Regarding the substantive grounds for the proceeding, the Show Cause Order alleged that on April 17, 2017, the Osteopathic Medical Board of California (OMBC) "adopted the Proposed Decision of an Administrative Law Judge . . . recommending revocation of" Respondent's "Osteopathic Physician's License," effective on May 17, 2017. *Id.* As a result, the Order alleged that Respondent is "without authority to handle controlled substances in the State of California, the [S]tate in which [he is] registered with DEA." *Id.* at 1–2. Based on his "lack of authority to [dispense] controlled substances in . . . California," the Order asserted that "DEA must revoke" Respondent's registration. *Id.* at 2 (citing 21 U.S.C. 824(a)(3); 21 CFR 1301.37(b)).

The Show Cause Order notified Respondent of (1) his right to request a hearing on the allegations or to submit a written statement in lieu of a hearing, (2) the procedure for electing either option, and (3) the consequence for failing to elect either option. *Id.* (citing 21 CFR 1301.43). The Order also notified Respondent of his right to submit a corrective action plan. *Id.* at 2–3 (citing 21 U.S.C. 824(c)(2)(C)).

On October 15, 2018, Respondent filed a letter (dated October 9, 2018) indicating that the Show Cause Order was "delivered to [him] by DEA agents